Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.
Clinical trial NCT03737968 · UNKNOWN
Trial details
- NCT number
- NCT03737968
- Sponsor
- Yonsei University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-01-02
- Primary completion
- 2023-10-01
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.